Emerging Therapeutic Targets and Experimental Drugs for the Treatment of NAFLD

The two main subsets of nonalcoholic fatty liver disease (NAFLD) include: (1) nonalcoholic fatty liver (NAFL), the more common and non-progressive subtype; and (2) nonalcoholic steatohepatitis (NASH), the less common subtype, which has the potential to progress to advanced liver damage. Current trea...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Pratima Dibba, Andrew A. Li, Brandon J. Perumpail, Nimy John, Sandy Sallam, Neha D. Shah, Waiyee Kwong, George Cholankeril, Donghee Kim, Aijaz Ahmed
פורמט: Artigo
שפה:Inglês
יצא לאור: MDPI AG 2018-09-01
סדרה:Diseases
נושאים:
NAFLD
NASH
nonalcoholic fatty liver disease
drug therapy
chemokine receptor 2 and 5
galectin-3 protein
toll-like receptor 4
fibroblast growth factor 19
selective thyroid hormone receptor-beta
apoptosis signal-regulating kinase 1
acetyl-coenzyme A carboxylase
farnesoid X receptor
inflammasomes
גישה מקוונת:http://www.mdpi.com/2079-9721/6/3/83
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים